William Blair research analyst Sharon Zackfia shared her perspective on the restaurant industry’s economic outlook with Nation’s Restaurant News following the annual ICR conference.
“It feels more stable for them,” Zackfia said.
Equity Research
William Blair research analyst Sharon Zackfia shared her perspective on the restaurant industry’s economic outlook with Nation’s Restaurant News following the annual ICR conference.
“It feels more stable for them,” Zackfia said.
Stay up-to-date with the latest William Blair news and insights
William Blair initiated research coverage of Kalaris Therapeutics, Inc. (KLRS $7.08) and Ocular Therapeutix, Inc. (OCUL $6.36), both biotechnology companies developing therapies for the treatment of retinal vascular diseases.
Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures